MX377653B - Producto y uso para normalización de la viscoelasticidad del moco. - Google Patents
Producto y uso para normalización de la viscoelasticidad del moco.Info
- Publication number
- MX377653B MX377653B MX2015013040A MX2015013040A MX377653B MX 377653 B MX377653 B MX 377653B MX 2015013040 A MX2015013040 A MX 2015013040A MX 2015013040 A MX2015013040 A MX 2015013040A MX 377653 B MX377653 B MX 377653B
- Authority
- MX
- Mexico
- Prior art keywords
- normalization
- product
- mucus viscoelasticity
- mucus
- viscoelasticity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
- C12Y108/04—Oxidoreductases acting on sulfur groups as donors (1.8) with a disulfide as acceptor (1.8.4)
- C12Y108/0401—Adenylyl-sulfate reductase (thioredoxin) (1.8.4.10)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
- C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
- C12Y108/01009—Thioredoxin-disulfide reductase (1.8.1.9), i.e. thioredoxin-reductase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Analytical Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792198P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/030545 WO2014145735A2 (en) | 2013-03-15 | 2014-03-17 | Product and process for mucus viscosity normalization |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015013040A MX2015013040A (es) | 2016-05-24 |
| MX377653B true MX377653B (es) | 2025-03-11 |
Family
ID=51527945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015013040A MX377653B (es) | 2013-03-15 | 2014-03-17 | Producto y uso para normalización de la viscoelasticidad del moco. |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9168290B2 (enExample) |
| EP (1) | EP2968481B1 (enExample) |
| JP (1) | JP6672139B2 (enExample) |
| KR (2) | KR20210068606A (enExample) |
| CN (1) | CN105188738B (enExample) |
| AU (1) | AU2014232520B2 (enExample) |
| CA (1) | CA2906868A1 (enExample) |
| IL (1) | IL241320B (enExample) |
| MX (1) | MX377653B (enExample) |
| RU (1) | RU2750211C2 (enExample) |
| WO (1) | WO2014145735A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| KR20210068606A (ko) * | 2013-03-15 | 2021-06-09 | 오프로 테라퓨틱스 인코퍼레이션 | 점액 점도 정상화를 위한 생성물 및 방법 |
| EP3204358B1 (en) | 2014-10-07 | 2018-09-19 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| US10542961B2 (en) | 2015-06-15 | 2020-01-28 | The Research Foundation For The State University Of New York | System and method for infrasonic cardiac monitoring |
| CN106868090B (zh) * | 2017-03-28 | 2020-09-29 | 王绪友 | 一种医学检验用痰液处理方法 |
| CN107630065A (zh) * | 2017-11-02 | 2018-01-26 | 蔡慧娜 | 一种在支原体液体培养时使标本均匀分散的方法 |
| US20210213134A1 (en) * | 2018-05-17 | 2021-07-15 | Orpro Therapeutics, Inc. | Thiol-based multivalent drug delivery compositions |
| CA3163157A1 (en) * | 2020-01-03 | 2021-07-08 | Orpro Therapeutics, Inc. | Compositions having thioredoxin activity and related methods |
| CN115200954B (zh) * | 2022-06-28 | 2025-05-06 | 珠海大略科技有限公司 | 一种降低唾液粘度的方法及其应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3091569A (en) | 1960-08-26 | 1963-05-28 | Mead Johnson & Co | Mucolytic-nu-acylated sulfhydryl compositions and process for treating animal mucus |
| US3502779A (en) | 1966-08-18 | 1970-03-24 | Calbiochem | Process of mucolysis |
| US3683069A (en) * | 1970-02-19 | 1972-08-08 | Michel Hooreman | Enzymatic products which optimize the viscosity of mucuses and their applications |
| US4738841A (en) * | 1985-08-28 | 1988-04-19 | Repligen Corporation | Use of thioredoxin, thioredoxin-derived, or thioredoxin-like dithiol peptides in hair care preparations |
| US4771036A (en) | 1986-02-10 | 1988-09-13 | Trustees Of Columbia University In The City Of New York | Method and ophthalmic composition for the prevention and reversal of cataracts |
| SE8903003D0 (sv) | 1989-09-12 | 1989-09-12 | Astra Ab | Novel medical use |
| US5380758A (en) | 1991-03-29 | 1995-01-10 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5908611A (en) | 1995-05-05 | 1999-06-01 | The Scripps Research Institute | Treatment of viscous mucous-associated diseases |
| AU3643497A (en) | 1996-06-28 | 1998-01-21 | National Jewish Center For Immunology And Respiratory Medicine | Use of thioredoxin-like molecules for induction of mnsod to treat oxidative damage |
| JPH10191977A (ja) | 1997-01-14 | 1998-07-28 | Oriental Yeast Co Ltd | チオレドキシン改変体及び該改変体を含むａｐ−１の転写活性能を増強する因子 |
| DE19711052C2 (de) | 1997-03-03 | 1999-09-23 | Hans Rommelspacher | Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure als Mukolytikum |
| US7585645B2 (en) | 1997-05-27 | 2009-09-08 | Sembiosys Genetics Inc. | Thioredoxin and thioredoxin reductase containing oil body based products |
| US5925334A (en) | 1997-08-27 | 1999-07-20 | Rubin; Bruce K. | Use of surface active agents to promote mucus clearance |
| DE60233040D1 (de) | 2001-03-29 | 2009-09-03 | Synergy Pharmaceuticals Inc | Guanylat-cyclase-rezeptor-agonisten zur behandlung von gewebeentzündung und karzinogenese |
| CA2447407A1 (en) | 2001-05-04 | 2002-11-14 | Xencor | Nucleic acids and proteins with thioredoxin reductase activity |
| US20030194798A1 (en) | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
| US20060148057A1 (en) * | 2002-08-02 | 2006-07-06 | Wang Min | Thioredoxin mutants and uses thereof |
| KR20050072743A (ko) | 2002-09-10 | 2005-07-12 | 내셔날 쥬이쉬 메디칼 앤드 리서치 센터 | 점액 또는 타액의 액화를 위한 생성물 및 방법 |
| CN1694726A (zh) * | 2002-09-10 | 2005-11-09 | 国家杰威什医疗及研究中心 | 用于液化粘液或痰液的产品和方法 |
| US20090075871A2 (en) | 2003-03-31 | 2009-03-19 | National Institute Of Advanced Industrial Science And Technology | Modified Thioredoxin |
| RU2253484C1 (ru) * | 2003-09-30 | 2005-06-10 | Российский научный центр восстановительной медицины и курортологии Министерства здравоохранения Российской Федерации | Способ лечения хронического бронхолегочного процесса при врожденных пороках развития легких у детей |
| WO2005094269A2 (en) | 2004-03-24 | 2005-10-13 | National Jewish Medical And Research Center | Mucolytic and anti-elastase compounds and methods of use thereof |
| JP2008501772A (ja) | 2004-06-11 | 2008-01-24 | シンジェンタ リミテッド | 炎症性皮膚状態を寛解するための方法 |
| GB2416122A (en) | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
| GB0503640D0 (en) | 2005-02-22 | 2005-03-30 | Syngenta Ltd | Improvements in or relating to organic compounds |
| KR20210068606A (ko) | 2013-03-15 | 2021-06-09 | 오프로 테라퓨틱스 인코퍼레이션 | 점액 점도 정상화를 위한 생성물 및 방법 |
| US20210213134A1 (en) | 2018-05-17 | 2021-07-15 | Orpro Therapeutics, Inc. | Thiol-based multivalent drug delivery compositions |
| CA3163157A1 (en) | 2020-01-03 | 2021-07-08 | Orpro Therapeutics, Inc. | Compositions having thioredoxin activity and related methods |
-
2014
- 2014-03-17 KR KR1020217016634A patent/KR20210068606A/ko not_active Withdrawn
- 2014-03-17 EP EP14762649.3A patent/EP2968481B1/en active Active
- 2014-03-17 AU AU2014232520A patent/AU2014232520B2/en active Active
- 2014-03-17 US US14/216,568 patent/US9168290B2/en active Active
- 2014-03-17 CA CA2906868A patent/CA2906868A1/en active Pending
- 2014-03-17 RU RU2015143953A patent/RU2750211C2/ru active
- 2014-03-17 JP JP2016503417A patent/JP6672139B2/ja active Active
- 2014-03-17 CN CN201480024877.2A patent/CN105188738B/zh active Active
- 2014-03-17 KR KR1020157028723A patent/KR20160007496A/ko not_active Ceased
- 2014-03-17 WO PCT/US2014/030545 patent/WO2014145735A2/en not_active Ceased
- 2014-03-17 MX MX2015013040A patent/MX377653B/es active IP Right Grant
-
2015
- 2015-09-08 IL IL241320A patent/IL241320B/en unknown
- 2015-09-11 US US14/852,113 patent/US20160230149A1/en not_active Abandoned
-
2020
- 2020-11-23 US US17/101,588 patent/US12390511B2/en active Active
-
2025
- 2025-08-06 US US19/292,329 patent/US20260027189A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20260027189A1 (en) | 2026-01-29 |
| RU2015143953A (ru) | 2017-04-21 |
| AU2014232520B2 (en) | 2019-04-04 |
| CN105188738A (zh) | 2015-12-23 |
| EP2968481B1 (en) | 2020-11-04 |
| KR20210068606A (ko) | 2021-06-09 |
| RU2750211C2 (ru) | 2021-06-24 |
| WO2014145735A2 (en) | 2014-09-18 |
| US20210254025A1 (en) | 2021-08-19 |
| CN105188738B (zh) | 2025-11-07 |
| MX2015013040A (es) | 2016-05-24 |
| EP2968481A4 (en) | 2016-07-13 |
| HK1220354A1 (zh) | 2017-05-05 |
| WO2014145735A9 (en) | 2015-05-07 |
| AU2014232520A1 (en) | 2015-09-24 |
| IL241320B (en) | 2022-02-01 |
| US20160230149A1 (en) | 2016-08-11 |
| IL241320A0 (en) | 2015-11-30 |
| JP6672139B2 (ja) | 2020-03-25 |
| KR20160007496A (ko) | 2016-01-20 |
| RU2015143953A3 (enExample) | 2018-04-02 |
| US9168290B2 (en) | 2015-10-27 |
| US12390511B2 (en) | 2025-08-19 |
| NZ711983A (en) | 2021-09-24 |
| JP2016517446A (ja) | 2016-06-16 |
| US20140271599A1 (en) | 2014-09-18 |
| CA2906868A1 (en) | 2014-09-18 |
| EP2968481A2 (en) | 2016-01-20 |
| WO2014145735A3 (en) | 2014-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX377653B (es) | Producto y uso para normalización de la viscoelasticidad del moco. | |
| MX2017012206A (es) | Proliferacion ex vivo de celulas epiteliales. | |
| CL2012003075A1 (es) | Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion. | |
| HUE072090T2 (hu) | Magas viszkoelaszticitású és magas kohézióképességû hialuronsav töltõanyag | |
| BR112013003825A2 (pt) | conjugados, partículas, composições e métodos relacionados | |
| DOP2015000304A (es) | Inhibidores cristalinos de bromodominios | |
| UA114901C2 (uk) | Інгібітори асс та їх застосування | |
| WO2015002724A3 (en) | SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | |
| BR112014021325A2 (pt) | Formulação farmacêutica líquida e formulação liofilizada | |
| MX2021015789A (es) | Reduccion de la viscosidad de formulaciones farmaceuticas. | |
| EP3129465A4 (en) | Hydrogel compositions for use in cell expansion and differentiation | |
| BR112017005660A2 (pt) | novos ativadores de guanilato ciclase solúvel e sua utilização | |
| UY34008A (es) | ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?. | |
| MX386055B (es) | Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson. | |
| BR112016029013A2 (pt) | aperfeiçoamento em composição nasal e método de utilização do mesmo | |
| BR112015028703A2 (pt) | curativo de ferimentos compreendendo uma composição antimicrobiana | |
| WO2014153009A3 (en) | Thiosaccharide mucolytic agents | |
| BR112015032526A2 (pt) | composições anticaspa e métodos de uso das mesmas | |
| WO2014153495A3 (en) | Novel stat3 inhibitors | |
| WO2014146111A3 (en) | Analgesic compounds and methods of use | |
| EP4226936A3 (en) | Non-neuroinvasive viruses and uses thereof | |
| PH12018502139A1 (en) | Phosphaplatin liquid formulations | |
| CO2017002963A2 (es) | Espiro-tiazolonas | |
| AR105728A1 (es) | Lisobactina para su uso en el tratamiento de la mastitis bovina | |
| HK40017027A (en) | Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |